CHANGE MY LOCATION
Business and Finance
Business News
Employers cut 533K jobs in Nov., most in 34 years- Skittish employers slashed 533,000 jobs in November, the most in 34 years, catapulting the unemployment rate to 6.7 percent, dramatic proof the country is careening deeper into recession.
- News of a rapidly weakening job market put Wall Street on track for a sharply lower open Friday. The Labor Department's report that employers slashed 533,000 jobs in November had investors worrying about a long and deep recession.
Thailand reopens main international airport- Dancers, drummers and apologetic tourism officials greeted travelers Friday at the official reopening of Thailand's main international airport, which was shut down for a week by anti-government protesters.
US general spells out Iraq mission under new pact- A security pact that sets a timetable for troops to leave Iraq requires a shift in how the U.S. carries out combat missions during its remaining time in the country, the top U.S. military commander in Iraq said Friday.
- Stock intended to eventually earn taxpayers a profit as part of the Bush administration's massive bank bailout has lost a third of its value - about $9 billion - in barely one month, according to an Associated Press analysis. Shares in virtually every bank that received federal money have remained below the prices the government negotiated.
Auto bailout could be tied to gov't-run overhaul- The government would order a major restructuring of Detroit's struggling Big Three auto companies in exchange for a multibillion-dollar bailout under a plan circulating in Congress.
- Barack Obama, who rewrote the book on presidential fundraising, amassed more than $745 million during his marathon campaign, more than twice the amount obtained by his rival, Republican John McCain.
Hollywood's No. 1 women: Winfrey and Jolie- Oprah Winfrey tops The Hollywood Reporter's Power 100 list, an annual ranking of the most influential women in the entertainment industry.
- Armed robbers - some dressed in drag - made off with euro80 million ($100 million) in loot from a lightning-fast jewelry store theft in central Paris, in what police Friday called one of France's costliest jewel heists.
Giants' Pierce to meet with NYC investigators- Antonio Pierce is finally going to talk to investigators about what he did on the night Plaxico Burress shot himself.
KV Pharmaceutical Announces FDA Approval for Morphine ER 100 mg and 200 mg Tablets
ST. LOUIS
(Map)
-
While this is a highly genericized market, these two strengths have shown
unit market growth year-over-year according to IMS. When comparing the 12
months ended
ETHEX Corporation has commenced the launch of these two new strengths into its current line of 15 mg, 30 mg and 60 mg Morphine ER Tablets. The Company believes these two strengths will be a positive addition and will allow ETHEX to increase its market share position for its full product line offering.
About KV Pharmaceutical Company
KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets and acquires technology- distinguished branded and generic/non-branded prescription pharmaceutical products. The Company markets its technology-distinguished products through ETHEX Corporation, a national leader in pharmaceuticals that compete with branded products, and Ther-Rx Corporation, its branded prescription pharmaceutical subsidiary.
For further information about KV Pharmaceutical Company, please visit the Company's corporate website at www.kvpharmaceutical.com.
Safe Harbor
The information in this release may contain various forward-looking
statements within the meaning of the
All statements that address expectations or projections about the future, including without limitation, statements about the Company's strategy for growth, product development, product launches, regulatory approvals, market position, market share increases, acquisitions, revenues, expenditures and other financial results, are forward-looking statements.
All forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions, KV provides the following cautionary statements identifying important economic, political and technology factors, which among others, could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.
Such factors include (but are not limited to) the following: (1) changes
in the current and future business environment, including interest rates and
capital and consumer spending; (2) the difficulty of predicting FDA approvals,
including timing, and that any period of exclusivity may not be realized; (3)
acceptance and demand for new pharmaceutical products; (4) the impact of
competitive products and pricing, including as a result of so-called
authorized-generic drugs; (5) new product development and launch, including
the possibility that any product launch may be delayed or that product
acceptance may be less than anticipated, including with respect to our
Morphine ER tablets; (6) reliance on key strategic alliances; (7) the
availability of raw materials; (8) the regulatory environment, including
regulatory agency and judicial actions and changes in applicable law or
regulations; (9) fluctuations in revenues; (10) the difficulty of predicting
international regulatory approval, including timing; (11) the difficulty of
predicting the pattern of inventory movements by the Company's customers; (12)
the impact of competitive response to the Company's sales, marketing and
strategic efforts; (13) risks that the Company may not ultimately prevail in
litigation; (14) the proposed restatement of the Company's financial
statements for fiscal periods from 1996 through 2006 and for the quarter ended
This discussion is by no means exhaustive, but is designed to highlight important factors that may impact the Company's outlook. We are under no obligation to update any of the forward-looking statements after the date of this release.
|
|
